Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV tedisamil vs placebo for rapid conversion to sinus rhythm in recent onset atrial fibrillation or flutter (female subjects)
2004-000346-21Phase 3Completed
- Sponsor
- Solvay Pharmaceuticals
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Intravenous tedisamil with Placebo (2 arms). Primary endpoint: Conversion to normal sinus rhythm within 2.5 hours. Started Oct 2004; status: completed.
02
Drugs
tedisamil
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2004-000346-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000346-21.